<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:department>Pharmacology</gtr:department><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/DDD240F0-BF92-43B0-A7BA-57217BB59E46"><gtr:id>DDD240F0-BF92-43B0-A7BA-57217BB59E46</gtr:id><gtr:firstName>Trevor</gtr:firstName><gtr:surname>Sharp</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/4F3E2189-C0E5-406E-9F4F-6D3998C8E0D0"><gtr:id>4F3E2189-C0E5-406E-9F4F-6D3998C8E0D0</gtr:id><gtr:firstName>Grant</gtr:firstName><gtr:otherNames>Charles</gtr:otherNames><gtr:surname>Churchill</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/628381E0-FB6D-44E5-9F90-6A404E3731D0"><gtr:id>628381E0-FB6D-44E5-9F90-6A404E3731D0</gtr:id><gtr:firstName>Sridhar</gtr:firstName><gtr:surname>Vasudevan</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=BB%2FI532929%2F1"><gtr:id>DD9FCB8B-C256-41CE-A2A2-CD298F30FA03</gtr:id><gtr:title>Translational investigation of a lithium mimetic for treatment of bipolar disorder</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>BB/I532929/1</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:fund><gtr:end>2012-03-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/2512EF1C-401B-4222-9869-A770D4C5FAC7"><gtr:id>2512EF1C-401B-4222-9869-A770D4C5FAC7</gtr:id><gtr:name>BBSRC</gtr:name></gtr:funder><gtr:start>2011-03-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>126078</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>Based on our results from BBSRC Follow-on Funding, we have been granted a patent for the use of ebselen to treat bipolar disorder in both European and World-wide areas. Our tech transfer branch of Oxford University has been in discussions with about 20 big pharma and biotech companies and will take this forward as soon as we analyze the results form our current studies, which are also funded by with Follow-on Funding. 

Publication number EP2673048 A2
Publication type Application
Application number EP20120706085
Publication date Dec 18, 2013
Filing date Jan 18, 2012
Priority date Feb 9, 2011
Also published as WO2012107735A2, WO2012107735A3
Inventors Grant C. CHURCHILL, Sridhar R. VASUDEVAN, Nisha SINGH
Applicant Isis Innovation Limited</gtr:description><gtr:grantRef>BB/I532929/1</gtr:grantRef><gtr:id>64225BF2-4DA7-4260-B4A5-0E528F68440E</gtr:id><gtr:impact>It has fostered collaborative research on the drug ebselen. Funding (&amp;pound;1.4 M) from the MRC was secured for a study of impulsiveness in both a rat model and this will be translated into humans in an experimental medicine study. Funding from a Bipolar and Schizophrenia charity in the US called The Stanley Foundation has awarded ~&amp;pound;800,000 to fund a Phase 2, investigator-led efficacy trial for ebselen in bipolar disorder in Oxford. An American biotech company, Sound Pharmaceuticals, has taken a 3-year option on the license of the patent for ebselen and is funding the investigator-led clinical trial to the tune of about &amp;pound;500,000.</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>m-9859320940.31881776652152</gtr:outcomeId><gtr:patentId>EP2673048 A2, WO2012107735A2, WO2012107735A3</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Treatment of bipolar disorder</gtr:title><gtr:yearProtectionGranted>2014</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>D10D5037-357D-49D1-94EB-31E39E9832FE</gtr:id><gtr:title>Altered plasma glutathione levels in bipolar disorder indicates higher oxidative stress; a possible risk factor for illness onset despite normal brain-derived neurotrophic factor (BDNF) levels.</gtr:title><gtr:parentPublicationTitle>Psychological medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/25672ddc6807703349aab78acc4b20c0"><gtr:id>25672ddc6807703349aab78acc4b20c0</gtr:id><gtr:otherNames>Rosa AR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0033-2917</gtr:issn><gtr:outcomeId>545bc2826e4653.63335789</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C409B00C-02EA-4F36-AC7E-C3B0F3BBC011</gtr:id><gtr:title>A safe lithium mimetic? The inositol depletion hypothesis rescues an experimental drug for bipolar disorder</gtr:title><gtr:parentPublicationTitle>Biochemist</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0698031d3627be1b8a04e90feadcab2e"><gtr:id>0698031d3627be1b8a04e90feadcab2e</gtr:id><gtr:otherNames>Grant Churchill (Author)</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>r_710090270563c48c38</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>078CC395-6A11-47D2-9E00-0A0BD19E2885</gtr:id><gtr:title>Cloning, expression, purification, crystallization and X-ray analysis of inositol monophosphatase from Mus musculus and Homo sapiens.</gtr:title><gtr:parentPublicationTitle>Acta crystallographica. Section F, Structural biology and crystallization communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ced39d1f99179e5ffe5edc968b042a67"><gtr:id>ced39d1f99179e5ffe5edc968b042a67</gtr:id><gtr:otherNames>Singh N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1744-3091</gtr:issn><gtr:outcomeId>pm_5435b095b09e51c50</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4562F8C9-A367-4F3D-9A83-3FDB422204B8</gtr:id><gtr:title>A safe lithium mimetic for bipolar disorder.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ced39d1f99179e5ffe5edc968b042a67"><gtr:id>ced39d1f99179e5ffe5edc968b042a67</gtr:id><gtr:otherNames>Singh N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>pm_5435b095b09db7bb6</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">BB/I532929/1</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>